Moderna, Inc.: Moderna Announces Phase 1/2 Data on mRNA-3927

After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , American , Geralds Lipshutz , Los Angeles , Kyle Holen , Mary Beth Woodin , Lavina Talukdar , Head Of Development , American Society Of Gene , Wrd Communications , Moderna Inc , Nasdaq , Exchange Commission , Moderna Inc View , Cell Therapy , Annual Meeting , Propionic Acidemia , Interim Data , Gastrointestinal Diseases , David Geffen School , Senior Vice President , Private Securities Litigation Reform Act , Annual Report , Vice President , Inc View , Moderna , Nnounces , Hase , Data , Rna , 1927 , Investigational , Therapy , Propionic , Acidemia , Resented , 023 , Sgct , Nnual , Meeting ,